SERIES · Foundations
The Body’s Tiny Signal System
Peptides are short chains of amino acids that carry instructions. GLP-1 is one of them, but the signal system is much bigger.
GLP peptides shouldbe accessible.
The science, knowledge, and pricing.
Buy GLP-3Peptide Science /Explained
Understand how peptides work.
Read More: What Do Peptides Do? The Body’s Tiny Signal System
What comes after Ozempic
GLP-3Retatrutide
Weight loss. Metabolic and cardiovascular health. Liver function.
Target three of your body’s receptors.
GLP-1regulates appetite and insulin.
GIPsupports glucose handling.
Glucagonsignals the body to use stored energy (fat).
What the science shows.
28.7%
Average Body Weight Loss
86%
Reduction in Liver Fat
41%
Reduction in Triglycerides
In third-stage clinical trials.
The GLP Company We Wished Existed
Our Promise
At least 10% lowerprices by 2028.
A promise that goes further, the more of us there are.
What you should know.
Catalyst sells research peptides, not prescription medication. Retatrutide is being studied as a drug candidate by Eli Lilly, and Catalyst does not sell it for human use, medical treatment, diagnosis, or prevention.
Our products are designated Research Use Only and are intended for research purposes. That distinction matters: a compound can be available for laboratory research while a branded prescription drug is still moving through FDA review.
We do not provide dosing guidance, medical advice, or therapeutic claims.
Peptides labeled for research use do not require a prescription. They sit in a separate regulatory category, so the prescription requirement does not apply. Catalyst operates within the research-use-only (RUO) framework.
“Research Use Only” (RUO) is a regulatory designation under 21 CFR 809.10(c)(2). It applies to compounds manufactured and sold for non-clinical research, separate from products intended for diagnosis, treatment, or prevention of disease.
No. Catalyst does not provide medical advice, diagnosis, or treatment recommendations. The content on Science Explained, the lab reports, and the third-party COAs is education about published research, not medical guidance.
What comes after Ozempic
GLP-3 /Retatrutide
Target three of your body’s receptors.
GLP-1regulates appetite and insulin.
GIPsupports glucose handling.
Glucagonsignals the body to use stored energy (fat).
Clinical data demonstrates advancements in weight management, liver function, and cardiovascular health.
In third-stage clinical trials.
Weight loss. Metabolic and cardiovascular health. Liver function.
28.7%
Average Body Weight Loss
86%
Reduction in Liver Fat
41%
Reduction in Triglycerides
The GLP Company We Wished Existed
At least 10% lower
prices by
A promise that goes further,
the more of us there are.
What you should know.
How can you sell a peptide that’s still in clinical trials?
Catalyst sells research peptides, not prescription medication. Retatrutide is being studied as a drug candidate by Eli Lilly, and Catalyst does not sell it for human use, medical treatment, diagnosis, or prevention.
Our products are designated Research Use Only and are intended for research purposes. That distinction matters: a compound can be available for laboratory research while a branded prescription drug is still moving through FDA review.
We do not provide dosing guidance, medical advice, or therapeutic claims.
Why are peptides available without a prescription?
Peptides labeled for research use do not require a prescription. They sit in a separate regulatory category, so the prescription requirement does not apply. Catalyst operates within the research-use-only (RUO) framework.
What does “Research Use Only” mean?
“Research Use Only” (RUO) is a regulatory designation under 21 CFR 809.10(c)(2). It applies to compounds manufactured and sold for non-clinical research, separate from products intended for diagnosis, treatment, or prevention of disease.
Is this a substitute for medical advice?
No. Catalyst does not provide medical advice, diagnosis, or treatment recommendations. The content on Science Explained, the lab reports, and the third-party COAs is education about published research, not medical guidance.